Division of Interventional Radiology, Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, 35249, USA.
Curr Oncol Rep. 2024 Jul;26(7):754-761. doi: 10.1007/s11912-024-01531-8. Epub 2024 May 20.
There is increasing incidence of renal cell carcinoma (RCC) with multiple treatment options currently available. The purpose of this review is to outline patient selection and technical approaches and present the current literature for percutaneous ablation of T1b (4.1-7 cm) RCC.
An increasing number of retrospective studies and meta-analyses have evaluated the use of percutaneous ablation for T1b RCC. Overall, these studies tend to show that percutaneous ablation in this patient population is feasible. However, rates of major adverse events and local recurrence after percutaneous ablation for T1b RCC are both higher than when ablation is used for smaller tumors. As such, a multi-disciplinary, patient-centered approach is required. Due to the increasing literature in this area, the most recent National Comprehensive Cancer Network (NCCN) guidelines include percutaneous ablation as an option for non-surgical patients with T1b RCC.
目前，肾细胞癌（RCC）的发病率不断上升，治疗方法也多种多样。本文旨在概述患者选择和技术方法，并介绍目前经皮消融治疗 T1b（4.1-7cm）RCC 的相关文献。
越来越多的回顾性研究和荟萃分析评估了经皮消融治疗 T1b RCC 的应用。总的来说，这些研究表明，经皮消融治疗该患者人群是可行的。然而，T1b RCC 经皮消融后主要不良事件和局部复发的发生率均高于消融治疗较小肿瘤的情况。因此，需要采用多学科、以患者为中心的方法。由于该领域的文献不断增加，最新的国家综合癌症网络（NCCN）指南将经皮消融作为 T1b RCC 非手术患者的一种选择。
